奥曲肽与乌司他丁联合治疗急性胰腺炎的临床效果观察

Clinical observation of combination of octreotide and ulinastatin in the treatment of severe acute pancreatitis

目的探讨奥曲肽与乌司他丁联合治疗急性胰腺炎的临床效果。方法选取2014年7月-2016年12月我院收治的118例急性胰腺炎患者,将其分为研究组和对照组,各59例,对照组患者予以单用奥曲肽治疗,研究组患者采用乌司他丁联合奥曲肽治疗,并比较不同组患者临床效果。结果研究组患者总有效率明显高于对照组(P<0.05);治疗前,研究组和对照组患者血尿淀粉酶相比差异不明显(P>0.05),但治疗后,研究组和对照组患者血尿淀粉酶均明显改善(P<0.05),研究组患者改善更为明显(P<0.05);研究组患者腹胀和腹痛缓解时间以及住院时间均明显优于对照组,差异有统计学意义(P<0.05)。结论乌司他丁联合奥曲肽在治疗急性胰腺炎方面临床疗效确切,不仅能改善患者临床症状,同时还能缩短住院时间。

Objective To investigate the clinical effect of octreotide combined with ulinastatin in the treat-ment of severe acute pancreatitis. Methods A total of 118 patients with severe pancreatitis were enrolled in our hospital from July 2014 to December 2016. They were randomly divided into study group and control group, with 59 cases in each group. The patients in the control group were treated with octreotide alone. Patients in the study group were treat-ed with ulinastatin combined with octreotide, and compared the clinical effcacy of different groups of patients. Results The total effective rate of the study group was signifcantly higher than that of the control group （P〈0.05）. There was no signifcant difference in serum amylase and urine amylase between the study group and the control group before treat-ment （P〉0.05）, and the levels of amylase and urinary amylase were signifcantly improved in the study group and the control group. The improvement of the study group was more obvious （P〈0.05）. The duration of relapse, abdominal dis-tension and abdominal pain were signifcantly better in the study group than those in the control group （P〈0.05）. Con-clusion Clinical effcacy of ulinastatin combined with octreotide in the treatment of severe acute pancreatitis is exact, not only to improve the clinical symptoms of patients, but also shorten the hospital stay.